Perivascular endothelial implants inhibit intimal hyperplasia in a model of arteriovenous fistulae: a safety and efficacy study in the pig.
Vascular access complications are a major problem in hemodialysis patients. Native arteriovenous fistulae, historically the preferred mode of access, have a patency rate of only 60% at 1 year. The most common mode of failure is due to progressive stenosis at the anastomotic site. We have previously demonstrated that perivascular endothelial cell implants inhibit intimal thickening following acute balloon injury in pigs and now seek to determine if these implants provide a similar benefit in the chronic and more complex injury model of arteriovenous anastomoses. Side-to-side femoral artery-femoral vein anastomoses were created in 24 domestic swine and the toxicological, biological and immunological responses to allogeneic endothelial cell implants were investigated 3 days and 1 and 2 months postoperatively. The anastomoses were wrapped with polymer matrices containing confluent porcine aortic endothelial cells (PAE; n = 14) or control matrices without cells (n = 10). PAE implants significantly reduced intimal hyperplasia at the anastomotic sites compared to controls by 68% (p < 0.05) at 2 months. The beneficial effects of the PAE implants were not due to differences in the rates of reendothelialization between the groups. No significant immunological response to the allogeneic endothelial cells that impacted on efficacy was detected in any of the pigs. No apparent toxicity was observed in any of the animals treated with endothelial implants. These data suggest that perivascular endothelial cell implants are safe and reduce early intimal hyperplasia in a porcine model of arteriovenous anastomoses.
Nugent
Helen M
HM
Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Groothuis
Adam
A
Seifert
Philip
P
Guerraro
J Luis
JL
Nedelman
Mark
M
Mohanakumar
T
T
Edelman
Elazer R
ER
D000818:Animals; D000906:Antibodies / Q000097:blood; D001011:Aorta / Q000166:cytology; D001166:Arteriovenous Shunt, Surgical / Q000379:methods*; D004730:Endothelium, Vascular / Q000276:immunology / Q000473:pathology / Q000637:transplantation*; D005263:Femoral Artery / Q000276:immunology / Q000473:pathology* / Q000601:surgery*; D005781:Gelatin Sponge, Absorbable / Q000494:pharmacology; D006085:Graft Survival / Q000276:immunology; D006490:Hemostatics / Q000494:pharmacology; D006965:Hyperplasia; D013601:T-Lymphocytes / Q000276:immunology; D017539:Tunica Intima / Q000276:immunology / Q000473:pathology; D014657:Vasculitis / Q000473:pathology
D000906:Antibodies; D006490:Hemostatics